Department of Cardiology, SRM Medical College Hospital and Research Centre, Chennai, India.
Department of Cardiology, NIMS Medical College, Jaipur, India.
Indian Heart J. 2022 Jan-Feb;74(1):66-68. doi: 10.1016/j.ihj.2021.12.006. Epub 2021 Dec 18.
High-intensity statins are the cornerstone of medical management in Acute Coronary Syndromes (ACS). However, their effect on neurocognition are less clear. In this prospective observational study, we gave guideline-directed high-intensity atorvastatin 40 mg to middle-aged statin-naïve ACS patients. Memory assessments were performed before and 6 months after statin therapy using 2 validated scales-the Post-Graduate Institute Memory Scale (PGI-MS), and the Logical Memory Passage Test (LMPT). There was no significant difference in the mean PGI-MS test scores (baseline 75.4 ± 7.9, 6months 76.5 ± 8.2;p = 0.26) or the overall composite scores (baseline 32.02 ± 3.2, 6months 32.8 ± 3.1; p = 0.20), after 6 months of statin use. There was a small improvement in immediate recall (baseline score 8.5 ± 2.5, 6 months 9.04 ± 1.8; p = 0.05), and delayed recall (baseline 6.1 ± 2.6, 6 months 6.9 ± 1.9, p = 0.002). High-intensity atorvastatin use did not affect memory at 6 months among statin-naïve middle-aged patients with ACS.
高强度他汀类药物是急性冠状动脉综合征（ACS）医学治疗的基石。然而，它们对神经认知的影响尚不清楚。在这项前瞻性观察研究中，我们给中年初治 ACS 患者给予指南指导的高强度阿托伐他汀 40mg。在他汀类药物治疗前和治疗后 6 个月使用 2 种经过验证的量表-研究生记忆量表（PGI-MS）和逻辑记忆段落测试（LMPT）进行记忆评估。他汀类药物治疗 6 个月后，PGI-MS 测试的平均分数（基线 75.4±7.9，6 个月 76.5±8.2；p=0.26）或总体综合分数（基线 32.02±3.2，6 个月 32.8±3.1；p=0.20）均无显著差异。他汀类药物使用 6 个月后，即时回忆（基线评分 8.5±2.5，6 个月 9.04±1.8；p=0.05）和延迟回忆（基线 6.1±2.6，6 个月 6.9±1.9，p=0.002）略有改善。高强度阿托伐他汀治疗在 6 个月内对 ACS 初治中年患者的记忆无影响。
